Illumina (NASDAQ:ILMN) CAO Sells $80,000.00 in Stock

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) CAO Scott Ericksen sold 500 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the transaction, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Trading Up 0.9%

NASDAQ ILMN traded up $1.44 on Monday, reaching $164.40. 2,190,398 shares of the company were exchanged, compared to its average volume of 1,870,274. The business’s fifty day moving average price is $133.73 and its 200 day moving average price is $132.09. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a fifty-two week low of $78.79 and a fifty-two week high of $165.97. The stock has a market capitalization of $24.87 billion, a P/E ratio of 29.89, a price-to-earnings-growth ratio of 2.70 and a beta of 1.50.

Get Illumina alerts:

Illumina (NASDAQ:ILMN – Get Free Report) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period last year, the firm posted $0.97 EPS. The company’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts forecast that Illumina, Inc. will post 5.2 earnings per share for the current year.

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday, May 14th. Guggenheim upped their price target on shares of Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Monday. Royal Bank Of Canada began coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target on the stock. Finally, Piper Sandler lowered their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $138.38.

Read Our Latest Report on Illumina

Hedge Funds Weigh In On Illumina

Large investors have recently made changes to their positions in the company. Glenmede Trust Co. NA increased its position in Illumina by 6.5% during the first quarter. Glenmede Trust Co. NA now owns 2,288 shares of the life sciences company’s stock worth $282,000 after purchasing an additional 140 shares during the last quarter. Groupama Asset Managment raised its holdings in Illumina by 3.7% during the first quarter. Groupama Asset Managment now owns 9,545 shares of the life sciences company’s stock worth $1,177,000 after purchasing an additional 340 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Illumina by 1.4% in the first quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock valued at $258,924,000 after buying an additional 29,094 shares during the last quarter. Bull Harbor Capital LLC acquired a new position in Illumina in the first quarter valued at $1,413,000. Finally, Arkadios Wealth Advisors raised its stake in shares of Illumina by 1.6% during the first quarter. Arkadios Wealth Advisors now owns 8,001 shares of the life sciences company’s stock valued at $986,000 after purchasing an additional 124 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Featured Articles

• Five stocks we like better than Illumina
• Why These Three Big Buybacks Are Sending Very Different Signals to Investors
• Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
• Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
• Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.